126 related articles for article (PubMed ID: 16513346)
21. BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells.
Choi HE; Yoo MS; Choi JH; Lee JY; Kim JH; Kim JH; Lee JK; Kim GI; Park Y; Chi YH; Paik SH; Lee JH; Lee KT
Bioorg Med Chem Lett; 2011 Nov; 21(21):6236-41. PubMed ID: 21963305
[TBL] [Abstract][Full Text] [Related]
22. Withaferin A Analogs That Target the AAA+ Chaperone p97.
Tao S; Tillotson J; Wijeratne EMK; Xu YM; Kang M; Wu T; Lau EC; Mesa C; Mason DJ; Brown RV; Clair JJ; Gunatilaka AAL; Zhang DD; Chapman E
ACS Chem Biol; 2015 Aug; 10(8):1916-1924. PubMed ID: 26006219
[TBL] [Abstract][Full Text] [Related]
23. R-(-)-beta-O-methylsynephrine, a natural product, inhibits VEGF-induced angiogenesis in vitro and in vivo.
Kim NH; Pham NB; Quinn RJ; Kwon HJ
Biochem Biophys Res Commun; 2010 Aug; 399(1):20-3. PubMed ID: 20643105
[TBL] [Abstract][Full Text] [Related]
24. Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells.
Liu S; Wu P; Ye D; Huang Y; Zhou X; Li Y; Cai L
Pharmacology; 2009; 84(1):17-23. PubMed ID: 19478549
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, in vitro and in vivo preliminary evaluation of anti-angiogenic properties of some pyrroloazaflavones.
Ferlin MG; Conconi MT; Urbani L; Oselladore B; Guidolin D; Di Liddo R; Parnigotto PP
Bioorg Med Chem; 2011 Jan; 19(1):448-57. PubMed ID: 21145750
[TBL] [Abstract][Full Text] [Related]
26. Molecular insight in the multifunctional activities of Withaferin A.
Vanden Berghe W; Sabbe L; Kaileh M; Haegeman G; Heyninck K
Biochem Pharmacol; 2012 Nov; 84(10):1282-91. PubMed ID: 22981382
[TBL] [Abstract][Full Text] [Related]
27. Modulating endothelial barrier function by targeting vimentin phosphorylation.
Liu T; Ghamloush MM; Aldawood A; Warburton R; Toksoz D; Hill NS; Tang DD; Kayyali US
J Cell Physiol; 2014 Oct; 229(10):1484-93. PubMed ID: 24648251
[TBL] [Abstract][Full Text] [Related]
28. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hamsa TP; Kuttan G
Eur J Pharmacol; 2010 Dec; 649(1-3):64-73. PubMed ID: 20858484
[TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
Schmidt JM; Tremblay GB; Pagé M; Mercure J; Feher M; Dunn-Dufault R; Peter MG; Redden PR
J Med Chem; 2003 Apr; 46(8):1289-92. PubMed ID: 12672229
[TBL] [Abstract][Full Text] [Related]
31. The sphingosine-1-phosphate derivative NHOBTD inhibits angiogenesis both in vitro and in vivo.
Kim BS; Park H; Ko SH; Lee WK; Kwon HJ
Biochem Biophys Res Commun; 2011 Sep; 413(2):189-93. PubMed ID: 21888894
[TBL] [Abstract][Full Text] [Related]
32. Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells.
Muniraj N; Siddharth S; Nagalingam A; Walker A; Woo J; Győrffy B; Gabrielson E; Saxena NK; Sharma D
Carcinogenesis; 2019 Sep; 40(9):1110-1120. PubMed ID: 30698683
[TBL] [Abstract][Full Text] [Related]
33. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
35. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668.
Zhang H; Issekutz AC
Am J Pathol; 2002 Jun; 160(6):2219-30. PubMed ID: 12057924
[TBL] [Abstract][Full Text] [Related]
36. Anti-angiogenic activities of nucleosides and nucleotides and their structure-activity relationship.
Tsukamoto I; Konishi R; Kubota Y; Tokuda M; Sakakibara N; Maruyama T
Nucleic Acids Symp Ser (Oxf); 2007; (51):437-8. PubMed ID: 18029774
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
38. Nobiletin, a polymethoxylated flavonoid from citrus, shows anti-angiogenic activity in a zebrafish in vivo model and HUVEC in vitro model.
Lam KH; Alex D; Lam IK; Tsui SK; Yang ZF; Lee SM
J Cell Biochem; 2011 Nov; 112(11):3313-21. PubMed ID: 21748787
[TBL] [Abstract][Full Text] [Related]
39. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
40. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells.
Oh JH; Kwon TK
Int Immunopharmacol; 2009 May; 9(5):614-9. PubMed ID: 19236958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
